Highlights from EAU 2017 - Results from #60

Viewing 61-80 of 138 articles

EAU 2017: Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

EAU 2017: Systems pharmacology and quantitative proteomics for developing targeted triple therapy

EAU 2017: State of the Art Lecture: Enhanced Recovery After Surgery (ERAS) for Bladder Cancer: Non-Surgical Options to Improve Outcomes of Cystectomy

EAU 2017: State of the Art Debate - Evidence for extent of lymphadenectomy in urothelial bladder cancer

EAU 2017: Debate - Do we need to follow-up in low grade bladder tumor after 12 months?-Yes (EAU Guidelines)

EAU 2017: Perfect adjuvant treatment

EAU 2017: Perfect transurethral resection

EAU 2017: Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1ng/ml) worthwhile

EAU 2017: Comparing 20,000 open prostatectomy (RRP) cases to 5,000 robotic prostatectomy (RALP) cases, he noted no differences in oncologic outcome or urinary continence

EAU 2017: Quality of life after robotic, lap, and open surgery: real different?

EAU 2017: Debate on Kidney Cancer – partial nephrectomy is better done with the robot - Con

EAU 2017: Pure histological variants are associated with poor survival at radical cystectomy in patients with bladder cancer

EAU 2017: Efficacy of long acting sandostatin on reducing mucus production in patients with ileal neobladder

EAU 2017: Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013

EAU 2017: The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer

EAU 2017: 20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated

EAU 2017: Can pre-operative functional status (FS) or gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)?

EAU 2017: The diverse genomic landscape of low-risk prostate cancer

EAU 2017: Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml?

EAU 2017: Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

1
2
3
4
5
6
7